Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline | Stock Movers
Posted
June 22, 2026
Views
188
Likes
2
Engagement
1.06%
June 22, 2026
188
2
1.06%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
4:28Now PlayingToday's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report.
- Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn’t need to conduct additional studies of the drug.
- SpaceX (SPCX) is lower this morning, continuing its slide after its record IPO.
See omnystudio.com/listener () for privacy information.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Check out more episodes of Stock Movers
Follow Bloomberg Podcasts on Twitter
Visit our other YouTube channels:
Bloomberg Television
Bloomberg Originals
For coverage on news, markets and more
#Stocks #Markets #Finance #Investing #Podcast #Bloomberg
Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
